United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - enalapril maleate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - enalapril maleate - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - indometacin - oral capsule - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - indometacin - oral capsule - 50mg

Israel - English - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - tablets - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar 50 mg is indicated for the treatment of hypertensionheart failure: ocsaar 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to ocsaar 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: ocsaar 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of ocsaar 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - simvastatin -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - simvastatin -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - simvastatin -

Israel - English - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - tablets controlled release - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - desogestrel - oral tablet - 75microgram